CAMBRIDGE, Mass. , Jan. 4, 2022 /PRNewswire/ — Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and progression of new remedies for patients with severe hematological diseases, today announced the appointment of Jay T. Backstrom, MD, MPH, to its Board of Directors, and the appointment of Rahul Khara, Pharm. D. , JD, as General Counsel. Backstrom maximum recently executive vice president, head of research and development at Acceleron Pharma and Dr. Khara maximum recently vice president, chief legal and compliance officer, also at Acceleron Pharma.
“I am thrilled to welcome Jay and Rahul, both delight leaders, to the Disk Medicine team,” said Executive Director John Quisel, JD, Ph. D. Hematology chart through the critical stages of clinical progression and regulatory approval, and we look forward to reaping the benefits of their expertise as we prepare to bring our own line of new investigational treatments for hematological diseases across multiple patient studies. , Rahul’s extensive legal experience in a wide diversity of areas, adding corporate governance, compliance and marketing, will be invaluable.
“I am thrilled to enroll on Disc Medicine’s Board of Directors in this exciting bankruptcy in the company’s history as it transforms into a hematology company with multiple clinical systems in development,” said Dr. Backstrom, “I am inspired by the team’s determination to innovate, clinical rigor and make a difference in patients’ lives, and I look forward to share my delight as Disc realizes his vision to build a leading hematology company. “
“I am excited to enroll in the leadership of Disc Medicine and lead the legal and compliance purposes as we become a fully incorporated biotechnology company,” said Dr. Khara.
Dr. Backstrom joins the Board of Disc Medicine with over 30 years of studies and experience in progression. He most recently served as Executive Vice President, Head of Research and Development at Acceleron and was in the past Chief Medical Officer (and Head of Regulatory Affairs) at Celgene, which he joined in 2008 as Vice President of Clinical Research and Development, specializing in Hematology and Oncology. Prior to Celgene, he served as vice president of global medical and safety at Pharmion. Backstrom began his career at Marion Merrell Dow and continued with successor corporations by adding Hoechst Marion Roussel. Prior to his professional career in the biotechnology industry, Dr. Backstrom was a working physician and medical director of Samuel U. Rodgers Community Health Center in Kansas City, Missouri Dr. Backstrom holds a Doctor of Medicine degree from Temple University School of Medicine and earned a graduate education in internal medicine at Temple University Hospital. She also earned a Master’s Degree in Public Health from Saint Louis University School of Public Health.
Dr. Khara joins Acceleron Disc Medicine as Vice President, Legal and Chief Compliance Officer. In this role, he led the advertising and legal compliance functions. During his time at Acceleron, Dr. Khara led or supported a wide variety of legal matters, as well as facilitating the launch of Reblozyl® (luspatercept-aamt), Acceleron’s first advertising product, the company’s industry compliance program, and Merck’s successful acquisition of the business. Prior to Acceleron, Dr. Khara worked at Arnold Law Firms.
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company committed to transforming the lives of patients with hematological disorders. We are building a portfolio of innovative, first-class healing applicants who follow the basic pathways of red blood mobile biology. remedies that strengthen and give hope to the many patients suffering from hematological diseases. For more information, visit www. discmedicine. com.
Watch the multimedia download content: https://www. prnewswire. com/news-releases/disc-medicine-appoints-jay-t-backstrom-md-mph-to-its-board-of-directors-and-rahul -khara-pharmd-jd-como-consejero-general-301453590. html
SOURCE OF THE DISC Medicine